Trial Profile

A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Jul 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Cyclophosphamide; Dexamethasone; Rituximab
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
Focus Therapeutic Use

Most Recent Events

05 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
10 Dec 2013 Results for Waldenstrom's macroglobulinemia cohort presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
27 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com